CORDIS Project
Funding breakdown and partner intelligence are Premium
Sign in and upgrade to Premium for EU contribution totals, consortium analytics, OpenAlex research context, and AI summaries. · 0 consortium intelligence fields visible of 1
Start free • Cancel anytime • 14-day refund guarantee
This project investigates the mechanisms of drug resistance in melanoma cells, focusing on the spatio-temporal dynamics of their response to B-Raf inhibitors. By studying the tumor microenvironment, the research aims to uncover how local signals contribute to drug tolerance and resistance.
Oncogenic signalling by kinases presents a significant opportunity for cancer therapy.
The B-Raf selective inhibitor, Vemurafenib, has shown great effect against B-Raf mutant melanoma patients.
However, drug resistance emerges in nearly every case.
Various mechanisms underlying this resistance are described, however these approaches usually overlook the heterogeneity of the tumour microenvironment, and do not provide information about the temporal aspects of drug response and eventual emergence…
THE FRANCIS CRICK INSTITUTE LIMITED
Partner organizations (coordinator is shown above), with normalized type and CORDIS activity type. Guests see up to 4 partners.
Similar projects, consortium collaboration history, frequent partners, and OpenAlex research context.
Guests see up to 5 EuroSciVoc fields.
Guests see up to 5 topics.
